2seventy bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

2seventy bio (Nasdaq: TSVT) has announced its participation in upcoming investor conferences. The management team will present at the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. These events will include virtual fireside chats, available via live webcasts on the company's website, with replays accessible for 30 days. 2seventy bio focuses on developing CAR T cell therapies for multiple myeloma, leveraging their deep understanding of immune responses to tumor cells. Their name reflects their mission to rapidly translate human thought into action, aiming to extend the lives of cancer patients.

Positive

• 2seventy bio's management team will present at prestigious investor conferences, enhancing visibility and investor relations.
• The company is developing the first FDA-approved CAR T cell therapy for multiple myeloma, showcasing their innovative capabilities.
• Live webcasts and replays of the presentations will be available, increasing accessibility and engagement with the investor community.

Negative

• The press release lacks detailed financial or clinical data, limiting immediate actionable insights for investors.
• No updates on revenue or profit metrics are provided, leaving investors without concrete financial performance indicators.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- 2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences:

• TD Cowen 5^th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET
• Goldman Sachs 45^th Annual Global Healthcare Conference in Miami Beach, FL, on Monday, June 10, 2024 at 8:40 a.m. ET

Live webcasts of the fireside chats will be available via the Investors and Media section of the company’s website at https://ir.2seventybio.com. Replays will be archived on the 2seventy bio website for 30 days following the events.

About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522999662/en/

Investors:

Vicki Eatwell, CFO

vicki.eatwell@2seventybio.com



Media:

Jenn Snyder

Jenn.snyder@2seventybio.com

Source: 2seventy bio, Inc.

FAQ

When will 2seventy bio present at the TD Cowen 5th Annual Oncology Innovation Summit?

2seventy bio will present at the TD Cowen 5th Annual Oncology Innovation Summit on May 28, 2024.

What is the date for 2seventy bio's presentation at the Goldman Sachs 45th Annual Global Healthcare Conference?

2seventy bio will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.

How can investors access 2seventy bio's conference presentations?

Investors can access live webcasts and replays of the presentations via the company's website in the Investors and Media section.

What therapy is 2seventy bio developing for multiple myeloma?

2seventy bio is developing the first FDA-approved CAR T cell therapy for multiple myeloma.